The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association between aromatase inhibitor treatment (AIT) and ischaemic cardiotoxicity ...

Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China ...

Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

Discover the role of phytoestrogens, including soy, in menopause management and breast cancer prevention. Learn how these ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration ... for Lilly to acquire Scorpion's PI3Kα inhibitor program STX-478. STX-478 is a once-daily oral ...

“Most foods are processed in some way, for example to enable preservation”, says Huntriss, “but the term ‘ultra-processed’ refers to foods that often have a long ingredients ...

The new approval covers Kisqali's use in combination with an aromatase inhibitor (AI ... placebo-controlled food challenge after six months of treatment. The company filed its bid for approval ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

February 7, 2025 • There is one economic riddle ahead of Super Bowl Sunday: The egg market has been hit hard by avian flu, but wings are abundant and relatively affordable this year. So what gives?